#1 Clinical Trials Search in Europe

Dirocaftor

Dirocaftor is a promising drug being studied in clinical trials for the treatment of cystic fibrosis (CF). These trials aim to assess the efficacy and safety of Dirocaftor when used in combination with other drugs (Posenacaftor and Nesolicaftor) in adults with CF who have rare genetic mutations. The studies are designed to help researchers understand how well this drug combination works in improving lung function and other important aspects of CF management.

Table of Contents

What is DIROCAFTOR?

DIROCAFTOR, also known as PTI-808, is a promising new medication being developed to treat cystic fibrosis (CF), a genetic disorder that affects the lungs and other organs[1]. It is part of a combination therapy that includes two other drugs: posenacaftor and nesolicaftor. This combination is being studied for its potential to help CF patients with rare genetic mutations that are not typically responsive to existing treatments[2].

How DIROCAFTOR Works

DIROCAFTOR belongs to a class of drugs called CFTR modulators. CFTR stands for Cystic Fibrosis Transmembrane Conductance Regulator, which is the protein affected in CF. This medication works by helping to improve the function of the faulty CFTR protein in people with certain genetic mutations[1]. By doing so, it aims to address the underlying cause of CF rather than just treating the symptoms.

Clinical Trials Involving DIROCAFTOR

DIROCAFTOR is currently being studied in clinical trials to evaluate its safety and effectiveness. Two notable studies are:

  1. The CHOICES study (Phase III): This is a multicentre, randomized, double-blind, placebo-controlled, crossover study evaluating the efficacy and safety of the combination of dirocaftor, posenacaftor, and nesolicaftor in CF patients aged 18 years or older[1].
  2. A Phase IIb study: This study has a similar design to the CHOICES study but focuses on evaluating the efficacy and safety of the drug combination in CF patients with rare CFTR mutations[2].

Both studies aim to assess how well the drug combination works compared to a placebo over an 8-week treatment period.

Who Can Benefit from DIROCAFTOR?

DIROCAFTOR is being studied specifically for CF patients with rare CFTR mutations. This includes:

  • Patients aged 18 years or older
  • Those with a confirmed CF diagnosis
  • Patients with stable CF disease
  • Individuals with lung function (FEV1) between 40% and 90% of predicted normal values

It’s important to note that patients with certain common CF mutations (like F508del) or those currently taking other CFTR modulators are not eligible for these studies[1][2].

Dosage and Administration

In the clinical trials, DIROCAFTOR is administered as an oral capsule. The maximum daily dose being studied is 300 mg. The treatment period in the trials lasts up to 8 or 16 weeks[1][2]. However, the optimal dosage and duration of treatment will be determined based on the results of these studies.

Potential Benefits of DIROCAFTOR

The clinical trials are assessing several potential benefits of DIROCAFTOR, including:

  • Improvement in lung function, measured by forced expiratory volume in 1 second (FEV1)
  • Reduction in sweat chloride levels, which is an indicator of CFTR function
  • Increase in body weight
  • Improvement in quality of life, measured by the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain

These outcomes are being measured after 4, 6, and 8 weeks of treatment to assess both the short-term and sustained effects of the medication[1][2].

Safety and Side Effects

As with any new medication, safety is a crucial aspect being studied in the clinical trials. The researchers are monitoring for any adverse events or serious adverse events that may occur during treatment. They are also conducting regular assessments including:

  • Clinical laboratory tests (blood tests, urine analysis)
  • Physical examinations
  • Electrocardiography (ECG) to monitor heart function
  • Vital signs measurements

The full safety profile of DIROCAFTOR will be better understood once the clinical trials are completed[2].

Aspect Details
Drug Combination Dirocaftor/Posenacaftor/Nesolicaftor
Study Type Phase IIb and III, randomized, double-blind, placebo-controlled, crossover
Participant Age 18 years or older
Primary Endpoint Average ppFEV1 after 4, 6, and 8 weeks of treatment
Secondary Endpoints Sweat chloride levels, body weight, quality of life (CFQ-R), safety and tolerability
Key Inclusion Criteria Confirmed CF diagnosis, FEV1 40-90% predicted, BMI 16-30 kg/m²
Key Exclusion Criteria Common CFTR mutations, current use of CFTR modulators
Treatment Duration 8-16 weeks

FAQ

  • What is Dirocaftor and how is it being studied? Dirocaftor is a drug being investigated for the treatment of cystic fibrosis. It is being studied in combination with two other drugs, Posenacaftor and Nesolicaftor, in clinical trials involving adults with CF who have rare genetic mutations.
  • Who can participate in these clinical trials? The trials are open to adults (18 years or older) with confirmed cystic fibrosis diagnosis, clinically stable disease, and specific lung function criteria. Participants must not be currently taking other CFTR modulators and must meet other health-related requirements.
  • What is the main goal of these clinical trials? The main objective is to evaluate the effectiveness of the drug combination (Dirocaftor/Posenacaftor/Nesolicaftor) in improving lung function after 8 weeks of treatment compared to a placebo in CF patients with rare genetic mutations.
  • How is the effectiveness of the drug combination measured? The primary measure of effectiveness is the change in percent predicted forced expiratory volume in 1 second (ppFEV1), which is a measure of lung function. This is assessed by taking the average of measurements after 4, 6, and 8 weeks of treatment.
  • What other effects of the drug combination are being studied? The trials also look at other important factors such as changes in sweat chloride levels, body weight, quality of life (measured by a questionnaire), safety and tolerability of the drugs, and how the drugs are processed in the body (pharmacokinetics).

Ongoing Clinical Trials on Dirocaftor

  • Study on the Effects of Dirocaftor, Posenacaftor, and Nesolicaftor for Adults with Cystic Fibrosis

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark Germany Italy The Netherlands +3

  • Study on the Effects of Dirocaftor, Posenacaftor, and Nesolicaftor for Adults with Cystic Fibrosis

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Italy The Netherlands +3

Glossary

  • Cystic Fibrosis (CF): A genetic disorder that affects the lungs, pancreas, and other organs, causing thick, sticky mucus to build up and lead to infections and other complications.
  • CFTR: Cystic Fibrosis Transmembrane Conductance Regulator, the protein affected in cystic fibrosis.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function that represents the amount of air a person can forcefully exhale in one second.
  • ppFEV1: Percent predicted Forced Expiratory Volume in 1 second, a comparison of a person's FEV1 to the average FEV1 in the population for a person of similar age, sex, and body composition.
  • Sweat chloride test: A diagnostic test for cystic fibrosis that measures the concentration of chloride in a person's sweat.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Placebo: An inactive substance that looks like the drug being tested but has no medical effect, used as a control in clinical trials.
  • Double-blind: A study design where neither the participants nor the researchers directly involved know who is receiving the actual treatment and who is receiving a placebo.
  • Crossover study: A type of clinical trial where participants receive both the study treatment and the placebo at different times during the study, allowing each participant to serve as their own control.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-dirocaftor-posenacaftor-and-nesolicaftor-for-adults-with-cystic-fibrosis/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-dirocaftor-posenacaftor-and-nesolicaftor-for-adults-with-cystic-fibrosis-2/